Loading…
Loading…
SMLR (Semler Scientific, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
SMLR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SMLR and 80,000+ other tickers.
See exactly how SMLR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SMLR and 80,000+ other tickers.
Semler Scientific, Inc. develops and delivers cutting-edge technology solutions aimed at boosting the clinical effectiveness and operational efficiency of medical professionals throughout the United States. A flagship offering from the company is QuantaFlo, a rapid, four-minute diagnostic test performed in-office to assess blood flow. This tool allows healthcare providers to incorporate crucial blood flow measurements into their comprehensive evaluations of a patient's vascular health. Their clientele is diverse, spanning various medical specialties such as cardiology, internal medicine…
New York, New York--(Newsfile Corp. - January 22, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Semler Scientific (NASDAQ: SMLR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Semler Scientific caused the company to misrepresent or fail to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice into violations of the False Claims Act, while discussing possible violations of the False Claims Act (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, the Company's public statements were materially false and/or misleading at all relevant times.
Semler Scientific Inc. (NASDAQ: SMLR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price
Generali Asset Management SPA SGR lifted its position in Semler Scientific Inc. (NASDAQ: SMLR) by 42.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 100,000 shares of the company's stock after buying an additional 30,000 shares during the quarter. Generali Asset Management
Semler Scientific Inc. (NASDAQ: SMLR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target
Semler Scientific (NASDAQ: SMLR - Get Free Report) and Vasamed (OTCMKTS:VSMD - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Earnings and Valuation This table compares Semler Scientific and